|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
57,080,000 |
Market
Cap: |
177.52(M) |
Last
Volume: |
97,895 |
Avg
Vol: |
97,626 |
52
Week Range: |
$1.32 - $4.2 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 5.4 |
Insider 6 Months : 6.1 |
Insider 3/6 Months : 11.5 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, cancer and selected other diseases. Co.'s main galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. GR-MD-02 has the potential to treat various diseases due to galectin-3's involvement in multiple main biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
4,500 |
5,000 |
6,598 |
28,898 |
Total Buy Value |
$14,360 |
$15,253 |
$18,107 |
$54,541 |
Total People Bought |
3 |
4 |
4 |
5 |
Total Buy Transactions |
3 |
4 |
5 |
11 |
Total Shares Sold |
25,000 |
25,000 |
25,000 |
45,000 |
Total Sell Value |
$76,500 |
$76,500 |
$76,500 |
$118,240 |
Total People Sold |
1 |
1 |
1 |
2 |
Total Sell Transactions |
2 |
2 |
2 |
4 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Zordani Richard A. Jr. |
|
|
2024-04-30 |
4 |
B |
$3.52 |
$3,520 |
I/I |
1,000 |
1,000 |
0.01 |
-8% |
|
Lewis Joel |
President and CEO |
|
2024-04-24 |
4 |
B |
$3.39 |
$3,390 |
I/I |
1,000 |
2,000 |
0.01 |
-2% |
|
Czirr James C |
10% Owner |
|
2024-04-23 |
4 |
S |
$3.06 |
$11,252 |
I/I |
(3,677) |
5,922,207 |
|
4% |
|
Czirr James C |
10% Owner |
|
2024-04-22 |
4 |
S |
$3.06 |
$65,248 |
I/I |
(21,323) |
5,925,884 |
|
-6% |
|
Freeman Kevin D |
|
|
2024-04-22 |
4 |
B |
$2.98 |
$7,450 |
D/D |
2,500 |
25,969 |
0.01 |
6% |
|
Freeman Kevin D |
|
|
2024-04-09 |
4 |
A |
$0.00 |
$0 |
I/I |
2,063 |
18,063 |
|
- |
|
Lewis Joel |
President and CEO |
|
2024-03-01 |
4 |
A |
$1.96 |
$299,065 |
D/D |
152,584 |
897,716 |
|
- |
|
Uihlein Richard E |
|
|
2024-01-24 |
4 |
A |
$1.72 |
$40,000 |
D/D |
23,256 |
10,268,751 |
|
- |
|
Eldred Kary |
|
|
2024-01-16 |
4 |
B |
$1.79 |
$893 |
D/D |
500 |
49,313 |
0.01 |
77% |
|
Lewis Joel |
President and CEO |
|
2023-12-29 |
4 |
A |
$1.66 |
$19,266 |
D/D |
11,606 |
1,042,300 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-12-15 |
4 |
A |
$1.60 |
$19,267 |
D/D |
12,042 |
1,030,694 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-11-30 |
4 |
A |
$1.95 |
$19,266 |
D/D |
9,880 |
1,018,652 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-11-15 |
4 |
A |
$1.87 |
$19,267 |
D/D |
10,303 |
1,008,772 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-10-31 |
4 |
A |
$2.04 |
$19,266 |
D/D |
9,444 |
998,469 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-10-13 |
4/A |
A |
$2.01 |
$19,266 |
D/D |
9,585 |
989,025 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-10-13 |
4 |
A |
$2.01 |
$20,170 |
D/D |
10,035 |
989,025 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-09-29 |
4 |
A |
$1.92 |
$19,267 |
D/D |
10,035 |
979,440 |
|
- |
|
Uihlein Richard E |
|
|
2023-09-26 |
4 |
OE |
$3.00 |
$10,033,020 |
D/D |
2,236,204 |
10,235,495 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-09-15 |
4 |
A |
$1.76 |
$19,267 |
D/D |
10,947 |
969,405 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-08-15 |
4 |
A |
$1.60 |
$19,267 |
D/D |
12,042 |
947,448 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-07-31 |
4 |
A |
$1.50 |
$19,266 |
D/D |
12,844 |
935,406 |
|
- |
|
Eldred Kary |
|
|
2023-07-19 |
4 |
B |
$1.79 |
$2,854 |
D/D |
1,598 |
48,813 |
0.01 |
24% |
|
Lewis Joel |
President and CEO |
|
2023-07-14 |
4 |
A |
$1.63 |
$19,267 |
D/D |
11,820 |
922,562 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-06-30 |
4 |
A |
$1.44 |
$19,267 |
D/D |
13,380 |
911 |
|
- |
|
Lewis Joel |
President and CEO |
|
2023-06-15 |
4 |
A |
$1.46 |
$19,266 |
D/D |
13,196 |
897,362 |
|
- |
|
517 Records found
|
|
Page 1 of 21 |
|
|